We initiate coverage on Eli Lilly with a Buy rating and a $1,365 price target. Surging incretin volume and oral pipeline scaling will more than offset net price concessions, delivering $45.50 in 2027 EPS.
Key points
- 60% volume expansion in the latest quarter confirms underlying demand comfortably outruns ongoing net price concessions.
- $105.0 billion in 2027 revenue reflects expanding manufacturing capacity and oral GLP-1 adoption across commercial and government plans.
- $1,365 price target values Lilly at 30.0 times 2027 estimated earnings, offering 15% upside from current levels.
The call
The market price of $1,190 requires Lilly to deliver 28% earnings growth this year and maintain high-teens compounding through 2028. Investors worry that steep price cuts across China, Medicare, and commercial formularies will erode profit margins as volume growth inevitably matures. The market is too pessimistic about the durability of unit demand.
Quarterly revenue trajectory ($ billions)- Reported revenue
- Analyst forecast
Eli Lilly quarterly revenue ($B) reported from Q3 2024 to Q2 2026 and analyst forecast through Q4 2027E.
Volume gains will far exceed price degradation over the next twelve months. With additional manufacturing capacity entering production, oral Foundayo scaling globally, and next-generation triple-agonist retatrutide advancing to registration, operating margins will hold near 49%. Net income will reach $40.50 billion next year, driving sustained double-digit earnings growth.
Valuation
| Valuation driver | Estimate |
|---|
| FY2026 guided revenue midpoint | $86.0B |
| FY2027 estimated revenue | $105.0B |
| FY2027 estimated operating margin | 49.0% |
| FY2027 estimated net income | $40.50B |
| Diluted share count | 890.0M |
| FY2027 estimated EPS | $45.50 |
| Target P/E multiple | 30.0× |
| 12-month price target | $1,365.00 |
A 30 times multiple matches Lilly's multi-year earnings visibility and superior metabolic pipeline relative to large-cap biopharma peers. At $1,190, the risk-reward skew favors buyers as volume growth overcomes net price deflation. The 15% upside to our $1,365 target supports a buy rating.
Risks
- Steeper price concessions: deeper statutory rebates or commercial discounting could compress operating margin below 47%.
- Compounding litigation: legal or regulatory delays surrounding tirzepatide exclusivity could allow compounding pharmacies to undercut sales.
- Pipeline execution: manufacturing snags or delays in retatrutide filing would dampen medium-term terminal growth expectations.
What would change my mind
A sequential deceleration in U.S. incretin prescription growth below 15% accompanied by realized price declines wider than 15%.